Liquidia Co. (NASDAQ:LQDA) Receives Consensus Rating of “Buy” from Brokerages

Liquidia Co. (NASDAQ:LQDA) has been given a consensus rating of “Buy” by the nine analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $25.38.

LQDA has been the subject of several recent research reports. Wells Fargo & Company started coverage on Liquidia in a report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and set a $19.00 target price on shares of Liquidia in a report on Thursday, January 9th. Scotiabank began coverage on Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research note on Thursday, November 14th.

Insider Transactions at Liquidia

In other Liquidia news, CFO Michael Kaseta sold 23,370 shares of the company’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $275,298.60. Following the sale, the chief financial officer now owns 401,755 shares in the company, valued at approximately $4,732,673.90. This represents a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rajeev Saggar sold 2,445 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total transaction of $31,785.00. Following the sale, the insider now owns 267,943 shares in the company, valued at approximately $3,483,259. The trade was a 0.90 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 73,945 shares of company stock worth $874,403. 30.10% of the stock is currently owned by insiders.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of the business. Whitefort Capital Management LP raised its position in Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after buying an additional 927,546 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Liquidia by 144.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after purchasing an additional 230,820 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Liquidia by 855.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock worth $2,354,000 after purchasing an additional 210,753 shares during the period. Anson Funds Management LP bought a new stake in Liquidia during the third quarter valued at approximately $1,764,000. Finally, Sapient Capital LLC bought a new stake in Liquidia during the third quarter valued at approximately $1,336,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Stock Up 5.7 %

LQDA opened at $15.15 on Wednesday. Liquidia has a twelve month low of $8.26 and a twelve month high of $16.99. The company’s 50-day moving average price is $12.19 and its two-hundred day moving average price is $11.20. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -9.29 and a beta of 0.27.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).